Shots: Shots:

• Valneva will utilize its technology and platform capabilities to develop an inactivated- whole virus vaccine candidate- VLA2001 against COVID-19 while Dynavax will provide its CpG 1018- the adjuvant used in HEPLISAV-B which is the FDA’s approved vaccine for hepatitis B
• Valneva is leveraging its platform that was used for IXIARO- a vaccine against Japanese encephalitis and will utilize its BSL3 laboratory capabilities to rapidly leverage its large scale- Vero-based- viral GMP manufacturing facility in Scotland
• The combination of VLA2001 and CpG 1018 is expected to stimulate a strong immune response and generates high titers of neutralizing Ab. The companies will work with regulatory authorities to accelerate the clinical development path with an aim to initiate clinical studies before the end of 2020

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Valneva

Related News: Dynavax Signs an Agreement with Sinovac to Develop a Vaccine for COVID-19